{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "furosemide",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Edema : • Initial dose is 20 mg to 40 mg once given intramuscularly or intravenously.",
        "source": "US FDA label for furosemide (Furosemide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "If needed, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained.",
        "source": "US FDA label for furosemide (Furosemide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "Doses greater than 6 mg/kg body weight are not recommended ( 2.3 ) 2.1 General Considerations Inspect Furosemide Injection visually for particulate matter and discoloration before administration. 2.2 Recommended Dosage for Adults Edema Individualize therapy according to patient response.",
        "source": "US FDA label for furosemide (Furosemide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Published reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity [see Warnings and Precautions ( 5.3 )] .",
        "source": "US FDA label for furosemide (Furosemide), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "If needed, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained.",
        "source": "US FDA label for furosemide (Furosemide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "Doses greater than 6 mg/kg body weight are not recommended ( 2.3 ) 2.1 General Considerations Inspect Furosemide Injection visually for particulate matter and discoloration before administration. 2.2 Recommended Dosage for Adults Edema Individualize therapy according to patient response.",
        "source": "US FDA label for furosemide (Furosemide), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.",
        "source": "US FDA label for furosemide (Furosemide), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for furosemide (Furosemide), retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Available data from published observational studies, case reports, and postmarketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy.",
        "source": "US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations ) .",
        "source": "US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data ) .",
        "source": "US FDA label for furosemide (Furosemide), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group. 8.2 Lactation Risk Summary The presence of furosemide has been reported in human milk.",
        "source": "US FDA label for furosemide (Furosemide), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "There are no data on the effects on the breastfed infant or the effects on milk production.",
        "source": "US FDA label for furosemide (Furosemide), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      },
      {
        "text": "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition.",
        "source": "US FDA label for furosemide (Furosemide), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/furosemide.json",
        "verbatim": true
      }
    ]
  }
}